AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03957122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6
Study NCT02223390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving AIDS Care after Trauma (ImpACT)
Study NCT03395795 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NAVA
Description: The study has 3 phases:~1. Phase 1:~   The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~2. Phase 2:~   Switch to NAVA mode (1h).~  * Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~  * NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~3. Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording.
Study NCT03495336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee abstention phase
Description: no coffee consumption for 2 weeks
Study NCT03495336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LR Coffee consumption
Description: for 4 weeks participants consumed only LR Turkish coffee
Study NCT03495336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DR Coffee consumption
Description: for 4 weeks participants consumed only DR Turkish coffee
Study NCT00651989 — intervention group
Intervention type: OTHER
Intervention: optical coherence tomography foveal thickness measurement
Description: In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
Study NCT01994486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir and Sofosbuvir
Description: All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
Study NCT00085410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT02838602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ions therapy
Description: External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
Study NCT02838602 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Advanced external radiotherapy by Xrays or protons
Description: Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
Study NCT04295941 — intervention group
Intervention type: DRUG
Intervention: TraZODone Hydrochloride 300 MG
Description: Oral administration of Trazodone once-a-day.
Study NCT04511715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Bevacizumab IVB
Description: Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment
Study NCT04511715 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Follow-up with regular examination for determination of DR progression
Description: regular examination for determination of DR progression
Study NCT03965260 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bacterial samples from blood or peritoneal liquids
Description: For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance.
Study NCT04344821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curves Calcium
Description: Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)
Study NCT02792088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir 150mg
Description: Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Study NCT02792088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir 300mg
Description: Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Study NCT04344821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curves Calcium
Description: Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)
Study NCT04344821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose Placebo
Study NCT04344821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose Placebo
Study NCT02199782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Welsh language Cognitive Assessment
Description: This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
Study NCT02211300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The OptiScanner
Description: treatment of blood glucose per standard of care
Study NCT02211300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YSI 2300 STAT Plus™
Study NCT00081588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: 600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
Study NCT02185352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEEP regimen
Description: Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
Study NCT04499157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMOPTIC
Description: Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
Study NCT04499157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment of glaucoma
Description: Patients will receive only their usual treatment of glaucoma.
Study NCT03891212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placed in prone position for at least 16 consecutive hours a day.
Description: Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
Study NCT03609801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTV
Description: Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming.
Study NCT03609801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Duluth Model
Description: The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
Study NCT04155931 — intervention group
Intervention type: OTHER
Intervention: body temperature measurement
Description: Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
Study NCT01673334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration (FNA) and Core biopsy (FNB)
Study NCT04258020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: Bilevel Positive Airway Pressure (BiPAP) oxygen administration
Study NCT04258020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Heated High Flow Nasal Cannula oxygen administration
Study NCT03239041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social navigation team
Description: Social navigation team
Study NCT03760549 — intervention group
Intervention type: DRUG
Intervention: Subjects were administered NasoVAX high dose
Description: NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
Study NCT01820130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St Jude Medical EON mini rechargeable system
Description: implantation of Eon Mini Neurostimulation System (IPG Model 3788)
Study NCT00902616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: 3gm TDS for three months
Study NCT00902616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lactose powder
Description: 3gm TDS for 3 months
Study NCT02284737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PADN
Description: Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
Study NCT02284737 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham PADN
Description: The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
Study NCT02284737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
Study NCT02284737 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sildenafil
Description: Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
Study NCT02664428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PreBIOil
Description: A daily dose of about 90 gram will be given for 8 weeks
Study NCT02664428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A daily dose of about 90 gram will be given for 8 weeks
Study NCT00779246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal swabs for MRSA culture
Description: Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
Study NCT00779246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
Study NCT00779246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contact isolation
Description: All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
Study NCT04715594 — intervention group
Intervention type: DEVICE
Intervention: 1st-generation drug-eluting stent
Description: Implantation of 1st-generation drug-eluting stent
Study NCT04715594 — intervention group
Intervention type: DEVICE
Intervention: 2nd-generation drug-eluting stents
Description: Implantation of 2nd-generation drug-eluting stent
Study NCT01795001 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01946061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin
Description: Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
Study NCT01842828 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care plus electronic cigarettes
Study NCT01842828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care plus electronic cigarettes
Study NCT01842828 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard care
Study NCT04193202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Administered twice daily as an oral tablet of 45 mg
Study NCT04193202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered twice daily as a placebo oral tablet matching gefapixant
Study NCT03095417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise Intervention
Description: In home exercise intervention.
Study NCT03095417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Intervention
Description: In home exercise intervention.
Study NCT03095417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training Intervention
Description: Online cognitive training modules.
Study NCT03095417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training Intervention
Description: Online cognitive training modules.
Study NCT03095417 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching Control
Description: In home stretching.
Study NCT03095417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Control
Description: In home stretching.
Study NCT03095417 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Control
Description: Online control puzzles and games.
Study NCT03095417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Control
Description: Online control puzzles and games.
Study NCT04071873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care HIV testing
Description: Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
Study NCT04071873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing education
Description: Participants will be provided with education on community based HIV resources.
Study NCT02667912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal renal denervation
Description: Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
Study NCT02667912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional renal denervation
Description: Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
Study NCT01751568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
Study NCT01879709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Training
Description: Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
Study NCT01879709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
Study NCT01879709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided
Study NCT03451227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Description: The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.
Study NCT03451227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Group
Description: Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
Study NCT01063010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
Study NCT01063010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously for 90 minutes (+ 15 minutes)
Study NCT02755493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Study NCT00279149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visio conference system connected to the Tele-stroke network
Description: Visio conference system connected to the Tele-stroke network
Study NCT00650949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT997
Description: Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
Study NCT00650949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
Study NCT01144104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Service Announcement
Study NCT01144104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Multi-Media Computer Program
Study NCT01144104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Video
Study NCT04950335 — intervention group
Intervention type: PROCEDURE
Intervention: AOPT
Description: The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
Study NCT04950335 — intervention group
Intervention type: PROCEDURE
Intervention: AOCT
Description: Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.